Warfarin pharmacogenetics in a black Zimbabwean cohort : an observational prospective study
Aim: A prospective observational study was conducted to evaluate the feasibility of implementing clinical guidelines for warfarin dosing in black Zimbabwean patients. Methods: CYP2C9*5, CYP2C9*6, CYP2C9*8 and CYP2C9*11 and VKORC1 c. 1639 G>A variations were observed in 62 study patients. Results & Conclusion: Overall, 39/62 (62.90%) participants did not receive a warfarin starting dose as would have been recommended by Clinical Pharmacogenetics Implementation Consortium guidelines. US FDA and Dutch Pharmacogenetics Working Group guidelines are based on CYP2C9*2 and CYP2C9*3 only, hence, unlikely useful in this cohort, where such variants were not detected. Clinical Pharmacogenetics Implementation Consortium guidelines, on the other hand, have a specific recommendation on the African-specific variants CYP2C9*5, CYP2C9*6 and CYP2C9*11, and are hence suitable for implementation in Zimbabwe and would help optimize warfarin doses in patients in the study cohort.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 24(2023), 10 vom: 27. Juli, Seite 529-538 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
M Hidjo, Marie Madeleine [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.08.2023 Date Revised 16.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/pgs-2023-0089 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359365205 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359365205 | ||
| 003 | DE-627 | ||
| 005 | 20231226080721.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2023-0089 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1197.xml |
| 035 | |a (DE-627)NLM359365205 | ||
| 035 | |a (NLM)37435666 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a M Hidjo, Marie Madeleine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Warfarin pharmacogenetics in a black Zimbabwean cohort |b an observational prospective study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.08.2023 | ||
| 500 | |a Date Revised 16.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: A prospective observational study was conducted to evaluate the feasibility of implementing clinical guidelines for warfarin dosing in black Zimbabwean patients. Methods: CYP2C9*5, CYP2C9*6, CYP2C9*8 and CYP2C9*11 and VKORC1 c. 1639 G>A variations were observed in 62 study patients. Results & Conclusion: Overall, 39/62 (62.90%) participants did not receive a warfarin starting dose as would have been recommended by Clinical Pharmacogenetics Implementation Consortium guidelines. US FDA and Dutch Pharmacogenetics Working Group guidelines are based on CYP2C9*2 and CYP2C9*3 only, hence, unlikely useful in this cohort, where such variants were not detected. Clinical Pharmacogenetics Implementation Consortium guidelines, on the other hand, have a specific recommendation on the African-specific variants CYP2C9*5, CYP2C9*6 and CYP2C9*11, and are hence suitable for implementation in Zimbabwe and would help optimize warfarin doses in patients in the study cohort | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CYP2C9 | |
| 650 | 4 | |a VKORC1 | |
| 650 | 4 | |a genetic variation | |
| 650 | 4 | |a pharmacogenomics | |
| 650 | 4 | |a warfarin | |
| 650 | 7 | |a Warfarin |2 NLM | |
| 650 | 7 | |a 5Q7ZVV76EI |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 CYP2C9 |2 NLM | |
| 650 | 7 | |a EC 1.14.13.- |2 NLM | |
| 650 | 7 | |a Aryl Hydrocarbon Hydroxylases |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 650 | 7 | |a Vitamin K Epoxide Reductases |2 NLM | |
| 650 | 7 | |a EC 1.17.4.4 |2 NLM | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a VKORC1 protein, human |2 NLM | |
| 650 | 7 | |a EC 1.17.4.4 |2 NLM | |
| 700 | 1 | |a Chikwambi, Zedias |e verfasserin |4 aut | |
| 700 | 1 | |a Ngwende, Gift |e verfasserin |4 aut | |
| 700 | 1 | |a Matenga, Jonathan A |e verfasserin |4 aut | |
| 700 | 1 | |a Masimirembwa, Collen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 24(2023), 10 vom: 27. Juli, Seite 529-538 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:10 |g day:27 |g month:07 |g pages:529-538 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2023-0089 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 10 |b 27 |c 07 |h 529-538 | ||